Viatris (VTRS) Other Working Capital Changes (2020)
Viatris' (VTRS) quarterly Other Working Capital Changes came in at -$72.1 million in Q3 2020, down 1371.43% quarter-over-quarter from -$4.9 million in Q2 2020.
Viatris (VTRS) Other Working Capital Changes (2020) Analysis & Trends
Viatris' Other Working Capital Changes history runs 1 years deep, the most recent figure standing at -$72.1 million for Q3 2020.
- On a quarterly basis, Other Working Capital Changes fell 87.08% year-over-year to $22.9 million in Q1 2026; TTM through Mar 2026 was $479.4 million, a 121.94% increase from a year earlier, with the FY2025 full-year figure at $633.7 million, up 320.78% from the prior year.
- Other Working Capital Changes eased to $22.9 million in Q1 2026 per VTRS's latest filing, from $39.9 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $483.5 million in Q4 2022 and bottomed at -$263.4 million in Q3 2023.
- The 5-year median for Other Working Capital Changes is $111.8 million (2024), against an average of $108.2 million.
- Across the five-year window, Other Working Capital Changes slumped 301.68% in 2023 and soared 708.98% in 2025, its largest moves.
- Year by year, Other Working Capital Changes stood at $483.5 million in 2022, then tumbled by 45.83% to $261.9 million in 2023, then slumped by 66.28% to $88.3 million in 2024, then sank by 54.81% to $39.9 million in 2025, then tumbled by 42.61% to $22.9 million in 2026.
- Per Business Quant, the three latest VTRS Other Working Capital Changes figures stand at $22.9 million (Q1 2026), $39.9 million (Q4 2025), and $20.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 27, 2020 | -72.10 Mn |
| Sep 27, 2020 | -72.10 Mn |
| Sep 27, 2020 | -72.10 Mn |
| Jun 28, 2020 | -4.90 Mn |
| Jun 28, 2020 | -4.90 Mn |
| Jun 28, 2020 | -4.90 Mn |